OncoMatch/Clinical Trials/NCT06904313
Ultralow Dose PET Imaging for PSMA Expression
Is NCT06904313 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Piflufolastat F18 for healthy volunteer.
Treatment: Piflufolastat F18 — The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: psma-targeted therapy (lutetium-177)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nuclear Imaging Institute · Englewood, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06904313 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior psma-targeted therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 120 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify